Search results for "ROSIGLITAZONE"

showing 6 items of 26 documents

The Elastin-Derived Peptide VGVAPG Does Not Activate the Inflammatory Process in Mouse Cortical Astrocytes In Vitro.

2019

Abstract During vascular aging or in pathological conditions in humans, elastin is degraded and its by-products, the elastin-derived peptides (EDPs), enter the blood circulation. EDPs may be detected in the serum of healthy subjects or people who suffered a stroke. Moreover, recent evidence suggests a potential role of inflammatory mechanisms in neurological conditions, which are usually not categorized as inflammatory. Therefore, the present in vitro study was conducted to investigate the impact of the VGVAPG peptide on the activation of inflammatory process in mouse primary astrocytes, which were maintained in phenol red-free DMEM/F12 supplemented with 10% fetal bovine serum. The cells we…

0301 basic medicineNervous systemSOD1Primary Cell CultureGene ExpressionPeptideInflammationToxicologyRosiglitazone03 medical and health sciencesMice0302 clinical medicinemedicineAnimalschemistry.chemical_classificationInflammationbiologyChemistryGeneral NeuroscienceIn vitroCell biologyElastinElastin-derived peptides030104 developmental biologymedicine.anatomical_structureVGVAPGAstrocytesbiology.proteinOriginal Articlemedicine.symptomInflammation MediatorsPeptidesAstrocyteElastinOligopeptides030217 neurology & neurosurgeryFetal bovine serumAstrocyteNeurotoxicity research
researchProduct

Comparison of the effects of metformin and rosiglitazone in anovulatory women with polycystic ovary syndrome (PCOS)

2003

metformin rosiglitazone polycystic ovary syndrome (PCOS)
researchProduct

Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?

2011

Clinical evidence and the recent decisions of the European Medicines Agency and the Food and Drug Administration challenge the safety of thiazolidinediones treatment. Recently, this treatment has been suggested for Friedreich's ataxia because thiazolidinediones improve neurological symptoms. Hypertrophic cardiomyopathy is the most prevalent cardiac feature and the cause of premature death in Friedreich's ataxia patients. We recommend that therapy with peroxisome proliferator-activated receptor-gamma agonists like thiazolidinediones be taken with caution, as they cause a decrease in the number of fast fibers and an increase in mitochondrial biogenesis in cardiac muscle because of the inducti…

medicine.medical_specialtyAtaxiaHeart diseasebusiness.industryInsulinmedicine.medical_treatmentHypertrophic cardiomyopathymedicine.diseaseBioinformaticsEndocrinologyNeurologyMitochondrial biogenesisHeart failureInternal medicinemedicineNeurology (clinical)medicine.symptomRosiglitazonebusinessPioglitazonemedicine.drugMovement Disorders
researchProduct

A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.

2014

Scope Resveratrol may function as a chemopreventive agent. A recent clinical study demonstrates a reduction in tumor cell proliferation in colorectal patients receiving repeated oral ingestion of resveratrol. However, gaps remain in our knowledge of the molecular mechanisms by which resveratrol exerts its chemopreventive effect. We have previously demonstrated that resveratrol induces apoptosis in colon cancer cells and that resveratrol can sensitize chemoresistant colon cancer cells to various drugs. Based on its ability to activate peroxisome proliferator-activated receptor gamma (PPARγ) in colon cancer cells, we sought to determine the implication of this nuclear transcription factor in …

endocrine system diseasesColorectal cancerPeroxisome proliferator-activated receptorApoptosisPharmacologyResveratrolresveratrolMESH: ThiazolidinedionesPPAR[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compound0302 clinical medicineMESH: StilbenesStilbenesMESH : Cell Proliferation[ SHS.INFO ] Humanities and Social Sciences/Library and information sciencesAnilidesskin and connective tissue diseaseschemistry.chemical_classification0303 health sciencesfood and beveragesCell cycle3. Good healthMESH : ThiazolidinedionesMESH : Colonic Neoplasmscolon cancer030220 oncology & carcinogenesisColonic NeoplasmsS Phase Cell Cycle CheckpointsRosiglitazonehormones hormone substitutes and hormone antagonistsBiotechnologymedicine.drugMESH : PPAR gammaMESH: Cell Line Tumor[SHS.INFO]Humanities and Social Sciences/Library and information sciences[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyMESH: Anilides[SHS.INFO] Humanities and Social Sciences/Library and information sciencesMESH : AnilidesMESH : StilbenesRosiglitazone03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerCell Line TumorMESH: Cell Proliferationmedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BC] Life Sciences [q-bio]/Cellular BiologyMESH : S Phase Cell Cycle Checkpoints[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologypolyphenols030304 developmental biologyCell ProliferationMESH: Colonic NeoplasmsMESH: HumansCell growthMESH : Cell Line Tumor[ SDV.BC ] Life Sciences [q-bio]/Cellular Biologyorganic chemicalsMESH: ApoptosisMESH : Humansmedicine.diseasePPAR gammaMESH: S Phase Cell Cycle CheckpointschemistryMESH: PPAR gammaApoptosisCancer cellThiazolidinedionesMESH : ApoptosisFood Science
researchProduct

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-l…

2009

Udgivelsesdato: 2009-Jun-20 BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. METHODS: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A(1c) (HbA(1c)) of 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active con…

MaleMyocardial InfarctionAdministration OralType 2 diabeteslaw.inventionFractures BoneRandomized controlled triallawNeoplasmsClinical endpointMyocardial infarctionrosiglitazone; cardiovascular outcomesProspective StudiesDiureticsGeneral MedicineMiddle AgedMetforminMetforminHospitalizationStrokeDrug Therapy CombinationFemaleRosiglitazonemedicine.drugmedicine.medical_specialtyRosiglitazoneSex FactorsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAngina UnstableDiabetes Rosiglitazone Cardiovascular RiskHemoglobin A GlycosylatedGlycated HemoglobinHeart FailureIntention-to-treat analysisbusiness.industryBody WeightCholesterol HDLCholesterol LDLtype 2 diabetes; rosiglitazonemedicine.diseaseDrug UtilizationSurgerySulfonylurea CompoundsDiabetes Mellitus Type 2ThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLancet (London, England)
researchProduct

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.

2022

Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists (“glitazones”) are no longer prioritized due to their effects on heart failure. However, the association between these drugs and innovative therapies could be a valuable tool to attenuate the risk factors of the metabolic syndrome. Glitazones are used for the treatment of diabetes and associated comorbidities. There is substantial scientific evidence demonstrating the effect of glitazones at a cardiometabolic level, as well as on hematological and neurological pathologies that po…

RosiglitazoneDiabetes Mellitus Type 2PioglitazonePeroxisome Proliferator-Activated ReceptorsHumansHypoglycemic AgentsThiazolidinedionescardiovascular risk metabolic syndrome pioglitazone type 2 diabetes mellitusGeneral MedicineMedicina (Kaunas, Lithuania)
researchProduct